Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	37.73B +117.6%
Revenue (ttm)	17.26B +4.3%
Net Income	1.41B
EPS	1.21
Shares Out	1.16B
PE Ratio	26.78
Forward PE	12.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,512,225
Open	31.30
Previous Close	31.26
Day's Range	31.27 - 32.81
52-Week Range	13.04 - 37.35
Beta	0.76
Analysts	Strong Buy
Price Target	38.63 (+19.23%)
Earnings Date	Apr 29, 2026

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 33,950
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Analyst Summary

According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $38.63, which is an increase of 19.23% from the latest price.

Price Target

$38.63

(19.23% upside)

Analyst Consensus: Strong Buy